Genmab A/S Receives Hold Consensus Recommendation from Analysts, Continues Focus on Antibody Therapeutics for Cancer and Other Diseases
As of September 27, 2023, Genmab A/S (NASDAQ:GMAB) has received a "Hold" consensus recommendation from the fifteen analysts that cover ...